Insider Selling: Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Insider Sells 90,000 Shares of Stock

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) insider Michael Robert Martin sold 90,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 14th. The shares were sold at an average price of $21.19, for a total value of $1,907,100.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Michael Robert Martin also recently made the following trade(s):

  • On Friday, September 10th, Michael Robert Martin sold 25,000 shares of Aurinia Pharmaceuticals stock. The stock was sold at an average price of $19.80, for a total value of $495,000.00.
  • On Monday, August 9th, Michael Robert Martin sold 5,000 shares of Aurinia Pharmaceuticals stock. The stock was sold at an average price of $16.01, for a total value of $80,050.00.
  • On Wednesday, July 28th, Michael Robert Martin sold 5,000 shares of Aurinia Pharmaceuticals stock. The stock was sold at an average price of $13.86, for a total value of $69,300.00.
  • On Tuesday, June 22nd, Michael Robert Martin sold 5,000 shares of Aurinia Pharmaceuticals stock. The shares were sold at an average price of $13.76, for a total value of $68,800.00.

NASDAQ:AUPH opened at $21.50 on Wednesday. The firm has a market capitalization of $2.76 billion, a price-to-earnings ratio of -19.55 and a beta of 0.48. Aurinia Pharmaceuticals Inc. has a 1-year low of $9.72 and a 1-year high of $21.86. The business’s fifty day moving average price is $14.59 and its 200 day moving average price is $13.50.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its earnings results on Wednesday, August 4th. The biotechnology company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.02). Aurinia Pharmaceuticals had a negative return on equity of 36.98% and a negative net margin of 242.26%. The firm had revenue of $6.62 million during the quarter, compared to analyst estimates of $4.98 million. As a group, sell-side analysts anticipate that Aurinia Pharmaceuticals Inc. will post -1.34 earnings per share for the current year.

AUPH has been the subject of several research analyst reports. Zacks Investment Research upgraded Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, August 17th. SVB Leerink restated a “buy” rating on shares of Aurinia Pharmaceuticals in a report on Thursday, August 19th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, Aurinia Pharmaceuticals has an average rating of “Buy” and an average price target of $27.33.

A number of hedge funds have recently modified their holdings of the business. Parametric Portfolio Associates LLC increased its position in Aurinia Pharmaceuticals by 24.5% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 32,796 shares of the biotechnology company’s stock worth $425,000 after purchasing an additional 6,462 shares during the last quarter. Morgan Stanley increased its position in Aurinia Pharmaceuticals by 1,080.9% in the 2nd quarter. Morgan Stanley now owns 3,621,692 shares of the biotechnology company’s stock worth $46,936,000 after purchasing an additional 3,315,006 shares during the last quarter. Northern Oak Wealth Management Inc. increased its position in Aurinia Pharmaceuticals by 60.0% in the 2nd quarter. Northern Oak Wealth Management Inc. now owns 4,800 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 1,800 shares during the last quarter. Wells Fargo & Company MN boosted its stake in shares of Aurinia Pharmaceuticals by 3.2% during the 2nd quarter. Wells Fargo & Company MN now owns 788,283 shares of the biotechnology company’s stock worth $10,216,000 after acquiring an additional 24,462 shares in the last quarter. Finally, Weiss Multi Strategy Advisers LLC boosted its stake in shares of Aurinia Pharmaceuticals by 3.7% during the 2nd quarter. Weiss Multi Strategy Advisers LLC now owns 31,264 shares of the biotechnology company’s stock worth $405,000 after acquiring an additional 1,122 shares in the last quarter. 38.27% of the stock is currently owned by institutional investors.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.

Further Reading: The benefits and drawbacks of dollar cost averaging

Insider Buying and Selling by Quarter for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.